科研之友
微信
新浪微博
Facebook
分享链接
摘要
The rapid action of the long acting beta agonist formoterol allows it to be used as both a preventer and reliever in the management of asthma. The Symbicort (R) SMART dosing regime has been shown to reduce the number of asthma exacerbations.
The aim was to determine the current prescribing of Symbicort (R), the prescribing of the SMART regimen and the co-prescribing of a short acting beta agonist with this regimen by means of an audit of prescriptions dispensed in a pharmacy multiple in the UK.
Anonymised data were collected on a standard form. Symbicort (R) prescribing data for six months were extracted from the pharmacy Patient Medication Record (PMR). Data were stratified by age and analysed to determine adherence with Symbicort (R) SMART prescribing as defined by the UK product license.
Data were received from 51 of the 118 (43.2%) pharmacies contacted. Complete information from 2484 PMRs was included in the study. 2.81% (70/2484) of patients were prescribed SMART as defined by the UK summary of product characteristics. Of the 18-35 year age group 7.44% (27/363) were prescribed SMART correctly. However, Symbicort (R) was prescribed twice a day and when required, with either the co-prescription of a SABA, or at an unlicensed dose in 2.46% (61/2484) and 0.28% (7/2484) patients respectively.
The incidence of Symbicort (R) SMART prescribing in this study is low but may be underestimated due to unclear dosing instructions.
- 出版日期2011-6
